登录 | 注册    关注公众号  
微信公众号
搜索
 > 【NSP8】

NSP8信息

英文名称:SARS-CoV-2-3C-like-proteinase
中文名称:SARS冠状病毒2-3C样蛋白酶
靶点别称:Papain-like proteinase,p65 homolog,MPro,3CL-PRO,GFL,Growth factor-like peptide,Leader protein,Non-structural protein 1,Non-structural protein 10,Non-structural protein 7,Non-structural protein 6,Non-structural protein 4,Non-structural protein 3,Non-structural protein 2,Non-structural protein 11,Non-structural protein 8,Non-structural protein 9,nsp1,nsp10,nsp11,nsp2,nsp3,nsp4,nsp5,nsp6,nsp7,nsp8,nsp9,ORF1a polyprotein,SARS coronavirus main proteinase,Replicase polyprotein 1a,pp1a,PL-PRO,PL2-PRO
上市药物数量:5
临床药物数量:27
最高研发阶段:批准上市

NSP8产品列表

产品库
标签
属性
货号 物种 产品描述 蛋白结构 纯度 活性
NS8-C5149
SARS-CoV-2
SARS-CoV-2 (COVID-19) NSP8 Protein, His Tag
ACRO质量管理体系
 
评论(0)
 

NSP8 分子别名

NSP8,nsp8

NSP8 分子背景

NSP8, forms a hexadecamer with nsp7 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, may synthesize substantially longer products than oligonucleotide primers. To ultimately combat the emerging COVID-19 pandemic, it is desired to develop an effective and safe vaccine against this highly contagious disease caused by the SARS-CoV-2 coronavirus. By investigating the entire proteome of SARS-CoV-2, six proteins, including the S protein and five non-structural proteins (nsp3, 3CL-pro, and nsp8-10) were predicted to be adhesins, which are crucial to the viral adhering and host invasion. The S, nsp3, and nsp8 proteins were also predicted by Vaxign-ML to induce high protective antigenicity.

NSP8 前沿进展

NSP8上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验

NSP8临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验

消息提示

请输入您的联系方式,再点击提交!

确定